Reviewing Senestech (NASDAQ:SNES) & Omeros (NASDAQ:OMER)

Senestech (NASDAQ:SNES) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability.

Valuation and Earnings

This table compares Senestech and Omeros”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senestech	$1.86 million	6.09	-$6.18 million	($3.65)	-0.59
Omeros	N/A	N/A	-$156.82 million	($2.02)	-5.71

Senestech has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Senestech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Senestech and Omeros’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Senestech	-253.54%	-98.35%	-73.17%
Omeros	N/A	N/A	-52.38%

Institutional & Insider Ownership

5.2% of Senestech shares are held by institutional investors. Comparatively, 48.8% of Omeros shares are held by institutional investors. 5.3% of Senestech shares are held by company insiders. Comparatively, 12.9% of Omeros shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and price targets for Senestech and Omeros, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senestech	1	1	0	1	2.33
Omeros	1	1	2	1	2.60

Omeros has a consensus target price of $40.33, indicating a potential upside of 249.51%. Given Omeros’ stronger consensus rating and higher possible upside, analysts plainly believe Omeros is more favorable than Senestech.

Risk and Volatility

Senestech has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500. Comparatively, Omeros has a beta of 2.45, suggesting that its share price is 145% more volatile than the S&P 500.

Summary

Omeros beats Senestech on 10 of the 13 factors compared between the two stocks.

About Senestech

SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.